Zenas BioPharma (ZEN) Achieves Primary Endpoint in Phase 2 MoonStone MS Trial with Obexelimab

Zenas BioPharma (ZEN) reported February 10, 2026, that its Phase 2 MoonStone trial of obexelimab met its primary endpoint in relapsing multiple sclerosis (R-MS). The treatment demonstrated statistically significant reduction in relapse rates and preserved key neurological functions over 24 weeks, compared to placebo. The trial enrolled 210 patients with active R-MS, with results showing a 30% reduction in relapse risk in the treated group. ZEN plans to submit a New Drug Application in the first half of 2026, with a potential target for approval in late 2026.